10/14/2026
The FDA announced a new Rare Disease Framework Initiative today that could change how treatments for rare diseases are developed and reviewed.
Traditional clinical trials are often difficult or impossible for diseases with very small patient populations. There may be limited natural-history data, no validated biomarkers, and too few patients for a large placebo-controlled trial. FDA is acknowledging that these realities require a more practical approach.
The goal is to develop clearer and more consistent expectations based on the disease, the treatment being studied, patient needs, and the evidence that can realistically be collected. FDA is also considering greater use of patient and caregiver input, outside disease experts, innovative trial designs, and newer statistical methods.
This could help developers understand earlier what evidence FDA will require and how treatments such as ASOs, gene therapies, and other emerging approaches can be evaluated in very small populations.
This is the beginning of a process, not an immediate change in approval standards. Treatments will still need credible evidence of safety and effectiveness. The opportunity is to create a regulatory path that recognizes the realities of rare disease research while maintaining those protections.
FDA is holding a public meeting on October 28 and is asking patients, caregivers, advocates, researchers, and drug developers to help shape the framework. The foundation intends to attend in person and provide public comment.
For the rare disease community, this is an important opportunity to make sure the final approach reflects what families and researchers face every day.
Learn more:
https://www.fda.gov/news-events/press-announcements/fda-launches-rare-disease-framework-initiative-develop-holistic-fit-purpose-framework-rare-disease
